Geron CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

2 Mar 2026

GERN

10-K: Geron Reports Reduced Losses, RYTELO Sales Growth Amidst Legal Challenges

Geron Corporation reported a significant reduction in net losses for 2025, driven by initial RYTELO sales, while navigating ongoing legal proceedings and a strategic workforce reduction.

NASDAQ

27 Feb 2025

GERN

Geron CORP

10-K: Geron's 10-K Filing Reveals RYTELO's Commercial Launch and Future Plans

Geron's 10-K filing highlights the commercial launch of RYTELO, its strategy to maximize its value, and ongoing clinical trials for other indications.

NASDAQ

28 Feb 2024

GERN

Geron CORP

10-K: Geron Corporation Outlines Capital Structure and Regulatory Landscape in 10-K Filing

Geron Corporation's 10-K filing details its capital stock, potential anti-takeover measures, and the regulatory pathway for its lead drug candidate, imetelstat.